Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference in New York. Rick Barry, Cassava's Executive Chairman, will participate in a 'fireside chat' with Vernon T. Bernardino, PhD., Managing Director of Biotechnology Equity Research at H.C. Wainwright.

The event is scheduled for Monday, September 9th, from 3:00pm to 3:30pm Eastern Time. A live webcast will be available on Cassava Sciences' website, with an archived replay accessible for 90 days following the event. Registered institutional investors can request meetings with Cassava Sciences through the conference website.

News Market Reaction

-2.54%

1 alert

-2.54% News Effect

On the day this news was published, SAVA declined 2.54%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26^th Annual Global Investment Conference, being held in New York.

Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.

Event details follow:

Date:	Monday, September 9th
Time:	3:00pm to 3:30 Eastern Time
Webcast:	https://journey.ct.events/view/d574c934-b104-45ac-bf42-07f169ce0d11

A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com. An archived replay will be available for 90 days following the event.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com

FAQ

When is Cassava Sciences (SAVA) presenting at the H.C. Wainwright Global Investment Conference?

Cassava Sciences (SAVA) is presenting at the H.C. Wainwright Global Investment Conference on Monday, September 9th, from 3:00pm to 3:30pm Eastern Time.

Who will represent Cassava Sciences (SAVA) at the H.C. Wainwright conference?

Rick Barry, Cassava Sciences' Executive Chairman, will represent the company in a 'fireside chat' at the H.C. Wainwright conference.

How can investors access Cassava Sciences' (SAVA) presentation at the H.C. Wainwright conference?

Investors can access a live webcast of Cassava Sciences' (SAVA) presentation on the 'Investors' page of the company's website, www.CassavaSciences.com. An archived replay will be available for 90 days after the event.

What is the focus of Cassava Sciences' (SAVA) research?

Cassava Sciences (SAVA) is a clinical-stage biotechnology company focused on Alzheimer's disease research.

Can institutional investors meet with Cassava Sciences (SAVA) during the H.C. Wainwright conference?

Yes, registered institutional investors can request meetings with Cassava Sciences (SAVA) through the conference website www.hcwevents.com, subject to availability.